The information on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it and as such is considered to be a marketing communication.
Gilead Sciences is trading at $90.11, up 24% since it revealed better-than-expected first-quarter results in May. For the first three months of 2014 the company revealed an EPS of $1.48 and revenue of $4.99 billion, while analysts expected figures of $0.91 and $3.95 billion respectively.
Gilead's hepatitis C drug, which sells for $1000 per pill, greatly contributed to its strong sales early in the year, but it has opened the debate about the cost of medication. The company is facing competition in the hepatitis C drug market from AbbVie and Merck, but for the time being it would appear that Gilead Sciences is ahead of its rivals.
Gilead still has a successful HIV treatment business, and sales of its drugs Stribild and Atripla are performing well even though they are currently being eclipsed by the hepatitis C drug Sovaldi.
The stock is receiving support at the 50-day moving average of $83.46. A strong set of results could put the $100.00 level in its crosshairs within the next quarter.
Gilead Sciences is available to trade during IG’s extended hours. Here is a full list of US stocks available for extended hours trading.